

First Named
Inventor : Richard P. Jean-Pierre

Appln. No. : 10/670,595

Filed : September 25, 2003

Title : PRESCRIPTION DRUG COMPLIANCE
MONITORING SYSTEM

Docket No. : S863.12-0001

Group Art Unit:

Examiner:

INFORMATION DISCLOSURE STATEMENT

Commissioner For Patents
P.O. Box 1450
Alexandria, VA 22313-1450

I CERTIFY THAT THIS PAPER IS BEING SENT BY U.S. MAIL,
FIRST CLASS, TO THE ASSISTANT COMMISSIONER FOR
PATENTS, ALEXANDRIA, VA 22313, THIS 18 DAY OF

December, 2003.
[Signature]
PATENT ATTORNEY

Sir:

The enclosed PTO Form-1449 lists patents and publications submitted pursuant to 37 C.F.R. 1.97. Copies of the patents or publications are enclosed as necessary [if application filing date is after June 30, 2003, copies of U.S. patents and application publications are not required].

This application relies, under 35 U.S.C. 120, on the earlier filing date of prior Application No. _____, filed on _____. The following references, listed on the enclosed PTO Form 1449 were submitted to and/or cited by the Office in the prior application; therefore, under 37 C.F.R. 1.98(d), copies are not required to be provided herewith:

Submitted herewith is a copy (with English translation as appropriate) of an Official Search Report of the _____ Patent Office in counterpart foreign Application No. _____ filed _____.

The following foreign language documents and English language documents are believed to be equivalent or substantially equivalent:

FOREIGN LANGUAGE

ENGLISH LANGUAGE

TIME OF FILING

The Information Disclosure Statement is being filed:

1. X with the application or within three months of the filing date of a national application (other than a continued prosecution application under 37 C.F.R. 1.53(d)) or date of entry into the national stage of an international application or, to the best of the undersigned's knowledge, before the mailing

date of a first Office action on the merits or a first office action after the filing of a request for continued examination under 37 C.F.R. 1.114, whichever event occurs last. In accordance with 37 C.F.R. 1.97(b), no certification or fee is required.

2. ☐ after the time period specified in paragraph 1 above, but, to the best of the undersigned's knowledge, before the mailing date of a final action under 37 C.F.R. 1.113 or notice of allowance under 37 C.F.R. 1.311, or an action that otherwise closes prosecution of the application. In accordance with 37 C.F.R. 1.97(c), submitted herewith is:

(check either A or B below)

- A. ☐ a statement as specified in 37 C.F.R. 1.97(e), no fee is required.
B. ☐ the fee set forth in 37 C.F.R. 1.17(p) for submission of an Information Disclosure Statement under 37 C.F.R. 1.97(c).

3. ☐ after the mailing date of either a final action under 37 C.F.R. 1.113 or a Notice of Allowance under 37 C.F.R. 1.311, whichever occurs first, but on or before payment of the issue fee. Applicant petitions for consideration of this Information Disclosure Statement pursuant to 37 C.F.R. 1.97(d)(2). Applicant submits herewith:

- A. ☐ a statement as specified in 37 C.F.R. 1.97(e); and
B. ☐ the fee set forth in 37 C.F.R. 1.17(p).

STATEMENT

(only used if No. 2A or No. 3 above is checked)

The person(s) signing below states:

(check appropriate paragraph)

☐ that each item of information contained in the Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. 1.97(e)(1).


or

☐ that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the person signing the statement after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual

designated in 37 C.F.R. 1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. 1.97(e)(2).

Respectfully submitted,


KINNEY & LANGE, P.A.

By: 

David R. Fairbairn, Reg. No. 26,047
THE KINNEY & LANGE BUILDING
312 South Third Street
Minneapolis, MN 55415-1002
Telephone: (612) 339-1863
Fax: (612) 339-6580

DRF/CJB:hlw

FORM PTO-1449

Atty. Docket No.:
S863.12-0001Application No.:
10/670,595
 OFFICE OF PATENTS AND PUBLICATIONS FOR
 APPLICANT'S INFORMATION
 DISCLOSURE STATEMENT
First Named Inventor:
Richard P. Jean-PierreFiling Date:
September 25, 2003

Group Art:

U.S. PATENT DOCUMENTS

Examiner Initials	Document No.	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents
AA	US 2001/0009398 A1	07-26-2001	Sekura et al.
AB	US 2002/0027507 A1	03-07-2002	Yarin et al.
AC	US 2002/0169635 A1	11-14-2002	Shillingburg
AD	4,725,997	02-16-1988	Urquhart et al.
AE	5,289,157	02-22-1994	Rudick et al.
AF	5,646,912	07-08-1997	Cousin
AG	5,706,257	01-06-1998	Rothman et al.
AH	6,594,549	07-15-2003	Siegel
AI			
AJ			
AK			

FOREIGN PATENT DOCUMENTS

	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Translation Yes No
AL	EP 0 265 049 B1	01-07-1993	Urquhart	
AM	EP 0 298 627 A2	01-11-1989	McIntosh	
AN	WO 00/32097	06-08-2000	Brown	
AO	WO 95/09386	04-06-1995	Ward	

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

AP	
AQ	
AR	

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.